Hormonal contraception: Present and future

Drugs of Today

Volumn 44, Issue 12, 2008, Pages 905-923

  Benagiano, Giuseppe ^a   Bastianelli, Carlo ^a   Farris, Manuela ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL; CONTRACEPTIVE AGENT; CYPROTERONE ACETATE; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DIENOGEST; DIENOGEST PLUS ESTRADIOL VALERATE; DIENOGEST PLUS ETHINYLESTRADIOL; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ELCOMETRINE; ESTRADIOL; ESTRADIOL VALERATE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; GESTAGEN; GONANE DERIVATIVE; LEVONORGESTREL; MESTRANOL; MIFEPRISTONE; MINESSE; NANDROLONE DERIVATIVE; NOMEGESTROL; NORETHISTERONE ACETATE; NORETYNODREL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YASMINELLE;

APPLICATION SITE REACTION; BREAST TENDERNESS; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG WITHDRAWAL; EMERGENCY CONTRACEPTION; HEADACHE; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; HYPERANDROGENISM; LOW DRUG DOSE; MENORRHAGIA; MENSTRUAL CYCLE; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; ORAL CONTRACEPTION; PATIENT COMPLIANCE; PELVIS PAIN SYNDROME; REVIEW; UNSPECIFIED SIDE EFFECT; VAGINA DISCHARGE; VAGINA RING;

ADMINISTRATION, CUTANEOUS; CONTRACEPTION; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; DRUG ADMINISTRATION SCHEDULE; ESTROGENS; FEMALE; HUMANS; PREGNANCY; PROGESTINS;

EID: 61949257680     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.12.1299292     Document Type: Review

References (103)

1. Vessey, M., Mant, D., Smith, A., Yeates, D. Oral contraceptives and venous thromboembolism: Findings in a large prospective study. Br Med J (Clin Res Ed) 1986, 292(6519): 526.
2. Rosenberg, L., Palmer, J.R., Sands, M.I. et al. Modern oral contraceptives and cardiovascular diseases. Am J Obstet Gynecol 1997, 177(3): 707-15.
3. Martinez-Manautou, J., Cortez, V., Giner, J., Aznar, R., Casasola, J., Rudel, H.W. Low doses of progestogen as an approach to fertility control. Fertil Steril 1966, 17(1): 49-57.
4. Staffa, J.A., Newschaffer, C.J., Jones, J.K., Miller, V. Progestin and breast cancer: An epidemiological review. Fertil Steril 1992, 57(3): 473-91.
5. Yuzpe, A.A., Turlow, H.J., Ramzy, I., Leyson, J.I. Post-coital contraception - A pilot study. J Reprod Med 1974, 13(2): 53-8.
6. Goldzieher, J.W., Rudel, H.W. How the oral contraceptives came to be developed. JAMA 1974, 230(3): 421-5.
7. Inhoffen H.H., Logemann W., Hohlweg, W., Serini A. Unter Suchungen in der Sexualhormon-Reihe. Ber Deutsch Chem Gesellsch 1938, 71: 1024.
8. Csemiczky, G., Dieben, T., Coeling Bennink, H.J., Landgren, B.M. The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17β-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desogestrel only for 7 days. Contraception 1996, 54(6): 333-8.
9. Düsterberg, B., Ellman, H., Müller, U. et al. Three years clinical experience with a new low-dose oral contraceptive containing 20 mg ethinyl estradiol and 75 mg gestodene: Efficacy, cycle control and tolerability. In: Lopes, P., Killick, S.R. (Eds.). The New Option in Low-Dose Oral Contraception: Expanding the Gestodene Choice. Carnforth, UK: Parthenon Publishing, 1995, pp. 21-35.
10. Rekers, H. Multicenter trial of a monophasic oral contraceptive containing ethinyl estradiol and desogestrel. Acta Obstet Gynecol Scand 1988, 67(2): 171-4.
11. Carr, B.R. Uniqueness of oral contraceptive progestins. Contraception 1998, 58(3 Suppl.): 23S-27S.
12. El Etreby, M.F., Beier, S., Gunzel, P. Comparative endocrine pharmacodynamics of contraceptive steroids. In: Safety Requirements for Contraceptive Steroids. Michael, F. (Ed.). New York: Cambridge University Press, 1989, pp. 179-92.
13. El Etreby, M. F. Comparative aspects of the influence of contraceptive steroids on tumorigenesis in reproductive organs of experimental animal and man. In: Animal Model in Human Reproduction. Serio, M., Martini, L. (Eds.). New York: Raven Press, 1980, pp. 443-60.
14. Oettel, M., Kaufmann, G., Kurischko, A. [The endocrinologic profile of metabolites of the progestin dienogest]. Pharmazie 1993, 48(7): 541-5.
15. Basdevant, A., Pellisser, C., Conrad, J., Degrelle, H., Guyene, T.T., Thomas, J.L. Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women. Contraception 1991; 44(6): 599-605.
16. Foidart, J.M., Wuttke W., Bouw, G.M., Gerlinger, C., Heithecker, R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000, 5(2): 124-34.
17. Huber, H.J., Foidart, J.M., Wuttke W. et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000, 5(1): 25-34.
18. De Berardis, D., Serroni, N., Salerno, R.M., Ferro, F.M. Treatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol. Ther Clin Risk Manag 2007, 3(4): 585-90.
19. Fenton, C., Wellington, K., Moen Robinson, D.M. Drospirenone/ ethinylestradiol 3 mg/20 μg (24/4 day regimen): A review of its use in contraception, premenstual dysphoric disorder and moderate acne vulgaris. Drugs 2007, 67(12): 1749-65.
20. Junchen, M. Dienogest: Bindungs-studien an veschienden Rezeptor und Serum-protein. In: Teichman, AT. (Ed.). Dienogest- Praklink und Klinik eines neuen Gestagenes. Berlin: Walter de Gruyter Verlag, 1995, pp. 119-33.
21. Endrikat, J., Graeser, T., Mellinger, U., Ertan, K., Holz, C. Multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1 mg estradiol valerate/2 mg dienogest on hot flushes in postmenopausal women. Maturitas 2007, 58(2): 201-7.
22. Wiegratz, I., Lee, J.H., Kutschera, E. et al. Effect of dienogest-containing oral contraceptives on lipid metabolism. Contraception 2002, 65(3): 223-9.
23. Habenicht, U.-F. Unpublished data.
24. Zahrandnik, H.P., Goldberg, J., Andreas, J.O. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception 1998, 57(2): 103-9.
25. Sulak, P.J. Continuous oral contraception: Changing times. Best Pract Res Clin Obstet Gynaecol 2008, 22(2): 355-74.
26. Pincus, G. Control of Fertility. New York and London: Academic Press, 1965, p. 219.
27. Sullivan, H., Furniss, H., Spona, J., Elstein, M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity. Fertil Steril 1999, 72(1): 115-20.
28. Bachman, G., Sulak, P.J., Sampson-Landers, C., Benda, N., Marr, J. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone. Contraception 2004, 70(3): 191-8.
29. Nakajima, S.T., Archer, D.F., Ellman, H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 μg (Loestrin 24 Fe). Contraception 2007, 75(1): 16-22.
30. Benagiano, G., Pera, A., Bianchi, P. Management of endometriosis: Historical background and rationale for the use of steroid hormones. In: Lemay, A., Maheux, R. (Eds.). Understanding and Managing Endometriosis. Advances in Research and Practice. New York: Parthenon Publishing, 1999, pp. 211-8.
31. Anderson, F.D., Hait, H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003, 68(2): 89-96.
32. Kaunitz, A.M. Beyond the pill: New data and options in hormonal and intrauterine contraception. Am J Obstet Gynecol 2005, 192(4): 998-1004.
33. Anderson, F.D., Gibbons, W., Portman, D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 2006, 73(3): 229-34.
34. Archer, D.F., Jensen, J.T., Johnson, J.V. et al. Evaluation of a continuous regimen of levonorgestrel/ethinyl controlled trial. Obstet Gynecol 2001, 98(5Pt. 1):771-8.
35. Glasier, A.F., Smith, K.B., van der Spuy, Z.M. Amenorrhea associated with contraception - an international study on acceptability. Contraception 2003, 67(1): 1-8.
36. Kaiser Daily Women's Health Policy Report 5/22/2007.
37. Smallwood, G.H., Meador, M.L., Lenihan, J.P., Shangold, G.A., Fisher, A.C., Creasy, G.W.; ORTHO EVRA/EVRA 002 Study Group. Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol 2001, 98(5 Pt. 1): 799-805.
38. Stewart, F.H., Kaunitz, A.M., Laguardia K.D., Karvois, D.L., Fisher, A.C., Friedman, A.J. Extended use of transdermal norelgestromin/ethinyl estradiol: A randomized trial. Obstet Gynecol 2005, 105(6): 1389-96.
39. Audet, M.C., Moreau, M., Koltun, W.D. et al.; ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: A randomized controlled trial. JAMA 2001, 285(18): 2347-54.
40. Zieman, M., Guillebaud, J., Weisberg, E., Shangold, G.A., Fisher, A.C., Creasy, G.W. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: The analysis of pooled data. Fertil Steril 2002, 77(2 Suppl. 2): S13-18.
41. Pierson, R., Archer, D., Moreau, M., Shangold, G.A., Fisher, A.C., Creasy G.W. Ortho Evra/Evra versus oral contraceptives: Follicular development and ovulation in normal cycles after an intentional dosing error. Fertil Steril 2003, 80(1): 34-42.
42. Heger-Mahn, D., Warlimont, C,. Faustmann, T., Gerlinger, C., Klipping, C. Combined ethinylestradiol/gestodene contraceptive patch: Two-center, open label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers. Eur J Contracept Reprod Health Care 2004, 9(3): 173-81.
43. Hussein, A., Ahsan, F. The vagina as a route for systemic drug delivery. J Control Release 2005, 103(2): 301-13.
44. Upadhyay, D.D. New contraceptive choices. Population Reports 2005. Series M, No. 19. Johns Hopkins Bloomberg School of Public Health, Baltimore.
45. Diaz, S. Contraceptive vaginal rings. International Planned Parenthood Federation Medical Bulletin, 1999, 33: 3-4.
46. Bjarnadóttir, R.I., Tuppurainen, M., Killick, S.R. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol 2002, 186(3): 389-95.
47. Available at: http://www.clinicaltrials.com. Accessed on: October 10, 2007.
48. Weisberg, E., Brache, V., Alvaraz, F. et al. Clinical performance and menstrual bleeding patterns with three dosage combinations of a Nestorone progestogen/ethinyl estradiol contraceptive vaginal ring used on a bleeding-signaled regimen. Contraception 2005, 72(1): 46-52.
49. Sivin, I. Campodonico, I., Kiriwat, O. et al. The performance of levonorgestrel rod and Norplant contraceptive implants: A 5 year randomized study. Hum Reprod 1998, 13(12): 3371-8.
50. Croxatto, H.B., Mäkäräinen, N. Pharmacodynamics and efficacy of Implanon. An overview of the data. Contraception 1998, 58(6 Suppl.): 91S-97S.
51. Devoto, L., Kohen, P., Barnhart, K. et al. Hormonal profile, endometrial histology and ovarian ultrasound assessment during 1 year of nomegestrol acetate implant (Uniplant). Hum Reprod 1997, 12(4): 708-13.
52. Sivin, I., Croxatto, H., Bahamondes, L. et al Two-year performance of a Nestorone-releasing contraceptive implant: A three-center study of 300 women. Contraception 2004, 69(2): 137-44.
53. Massai, M.R., Díaz, S., Quinteros, E. et al. Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women. Contraception 2001, 64(6): 369-76.
54. Croxatto, H.B. Progestin implants. Steroids 2000, 65(10-11): 681-5.
55. Trussell, J. Contraceptive efficacy. In: Hatcher, R.A., Trussell, J., Stewart, F. et al. (Eds.). Contraceptive Technology. 18th ed. New York: Ardent Media, 2004.
56. Young, E. Spray-on female contraceptive to start trial. New Scientist (Sydney, Australia), Nov. 27, 2003.
57. Sitruk-Ware, R. Small, M., Kumar, N., Tsong, Y.Y., Sundaram, K., Jackanicz, T. Nestorone: Clinical applications for contraception and HRT. Steroids 2003, 68(10-13): 907-13.
58. Population Council. Transdermal Delivery Systems for Women: Contraceptive Gel. Available at: http://www.popcouncil.org/projects/BIO_ContraceptiveGel. html. Accessed on: July 25, 2008.
59. Carenza, L., Ermini, M., Pala, A., Benagiano, G. [Effect of intrauterine progesterone-releasing devices on the hypothalamic-hypophyseal- ovarian axis in women.] Patol Clin Ostet Ginec 1976, 4(3): 109-15.
60. Wan, L.S., Hsu, Y.C., Ganguly, M., Bigelow, B. Effects of the Progestasert on the menstrual pattern, ovarian steroid and endometrium. Contraception 1977, 16(4): 417-34.
61. Hagenfeldt, K., Landgren B.M. Contraception by intrauterine release of progesterone - effects on endometrial trace elements enzymes and steroids. J Steroid Biochem 1975, 6(6): 895-8.
62. Hagenfeldt, K., Landgren, B.M., Edstrom, K., Johannisson, E. Biochemical and morphological changes in the human endometrium induced by the Progestasert device. Contraception 1977, 16(2): 183-97.
63. Ermini, M., Carpino, F., Petrozza, V., Benagiano G. Distribution and effect on the endometrium of progesterone released from a progestasert device. Hum Reprod 1989, 4(3): 221-8.
64. Shaw, ST., Macaulay L.K., Aznar, R., Gonzalez-Angulo, A., Roy, S. Effect of progesterone-releasing intrauterine contraceptive device on endometrial blood vessels: A morphometric study. Am J Obstet Gynecol 1981, 141: 829-39.
65. Snowden, R. The Progestasert and ectopic pregnancy. Br Med J 1977, 2(6102): 1600-1
66. Nilsson, C.-G., Johansson, E.D., Luukkainen T. A D- norgestrel-releasing IUD. Contraception 1976, 13(4): 503-14.
67. Faculty of Family Planning and Reproductive Health Care. FFPRHC Guidance (April 2004). The levonorgestel releasing system (LNG-IUS) in contraception and reproductive health. J Fam Plann Reprod Health Care 2004, 30(2): 99-109.
68. Barbosa, I., Bakos, O., Olsson, S.E., Odlind, V., Johansson, E.D. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception 1990, 42(1): 51-66.
69. Nilsson, C.G., Lähteemäki, P.L., Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril 1984, 41(1): 52-5.
70. rench, R.S. Cowan, M., Mansour, D. et al. Levonorgestrel-releasing (20 μg/day) intrauterine systems (Mirena) compared with other methods of reversible contraception. BJOG 2000, 107(10): 1218-25.
71. Lukkainen, T. The levonorgestrel intrauterine system: Therapeutic aspects. Steroids 2000, 65(10-11): 699-702.
72. Irvine, G.A., Campbell-Brown, B.B., Lumsden, M.A. et al. Randomised comparative trial of levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998, 105(6): 592-8.
73. Luukkainen, T., Lähteenmäki, P., Toivonen, J. Levonorgestrel-releasing intrauterine device. Ann Med 1990, 22(2): 85-90
74. Andersson, K., Odlind, V., Rybo, G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: A randomized comparative trial. Contraception 1994, 49(1): 56-72.
75. Rivera R., Yacobson, I., Grimes, D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol 1999, 181(5 Pt. 1): 1263-9.
76. Jonsson, B., Landgren, B.M., Eneroth, P. Effects of various IUDs on the composition of cervical mucus. Contraception 1991, 43(5): 447-58.
77. Andersson, K., Batar, I., Rybo G. Return to fertility after removal of a levonorgestrel releasing intrauterine device and Nova T. Contraception 1992, 46(6): 575-84.
78. French, R.S., Cown, P.M., Mansour D.J et al. Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraception: Two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness. Health Technol Assess 2000, 4(7): i-vi, 1-107.
79. Stewart, A., Cummins, C., Gold, L., Jordan, R., Phillips, W. Effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: A systematic review. BJOG 2001, 108(1): 74-86.
80. Faculty of Family Planning and Reproductive Health Care. FFPRHC Guidance (April 2004). The levonorgestel releasing system (LNG-IUS) in contraception and reproductive health. J Fam Plann Reprod Health Care 2004, 30(2): 99-109.
81. Massai, M.R., Díaz, S., Jackanicz T., Croxatto H.B. Vaginal rings for contraception in lactating women. Steroids 2000, 65(10-11): 703-7.
82. Sitruk-Ware, R. Contraceptive development at the Population Council. Quoted by: Population Reports (44), 2004.
83. Brown, A., Cheng, L., Lin, S., Baird, D.T. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: A double-blind randomized controlled trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab 2002, 87(1): 63-70.
84. Croxatto, H.B., Salvatierra, A.M., Croxatto, H.D., Fuentealba, B. Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Hum Reprod 1993, 8(2): 201-7.
85. Lakha, F., Ho, P.C., Van der Spuy, Z.M. et al. A novel estrogen-free oral contraceptive pill for women: Multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum Reprod 2007, 22(9): 2428-36.
86. Yuzpe, A.A., Thurlow, H.J., Ramzy, I., Leyson, J.I. Post-coital contraception - A pilot study. J Reprod Med 1974, 13(2): 53-8.
87. Hoffman, K.O. Postcoital contraception: Experiences with ethynil estradiol/norgestrel and levonorgestrel only. In: Harrison, R.F., Bonnar, J., Thompson, W. (Eds.). Proceedings of the XIth Congress on Fertility and Sterility. Lancaster: MTP Press Ltd., 1984, pp. 311-6.
88. World Health Organization. Task Force on Post-Ovulatory Methods for Fertility Regulation. (Special Programme for Research Training in Human Reproduction.) Post coital contraception with levonorgestrel during the peri-ovulatory phase of the menstrual cycle. Contraception 1987, 36: 257-86.
89. Task Force on Postovulatory Methods of Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: A randomised trial. Lancet 1999, 353(9154): 697-702.
90. Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet 1998, 352(9126): 428-33.
91. von Hertzen, H., Piaggio, G., Ding, J. et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: A WHO multicentre randomised trial. Lancet 2002, 360(9348): 1803-10.
92. von Hertzen, H., Piaggio, G. Levonorgestrel and mifepristone in emergency contraception. Steroids 2003, 68(6-10): 1107-13.
93. International Medical Advisory Panel, International Planned Parenthood Federation. IMAP statement on emergency contraception. IPPF Med Bull 2004, 38(1): 1-3.
94. Croxatto, H.B., Fuentealba, B., Brache, V. et al. Effects of the Yuzpe regimen, given during the follicular phase, on ovarian function. Contraception 2002, 65(2): 121-8.
95. Trussell, J., Ellertson, C., Dortlinger, L. Effectiveness of the Yuzpe regimen of emergency contraception by cycle day of intercourse: Implications for mechanism of action. Contraception 2003, 67(3): 167-71.
96. andgren, B.M., Johannisson, E., Aedo, A.R., Kumar, A., Shi, Y.E. The effect of levonorgestrel administered in large doses at different stages of the cycles on ovarian function and endometrial morphology. Contraception 1989, 39(3): 275-89.
97. Durand, M., del Carmen Cravioto, M., Raymond, E.G. et al. On the mechanism of action of short-term levonorgestrel administration in emergency contraception. Contraception 2001, 64(4): 227-34.
98. Kesserü, E., Garmendia, F., Westphal, N., Parada, J. The hormonal peripheral effects of dl-norgestrel in post-coital contraception. Contraception 1974, 10(4): 411-24.
99. Ashok, P.W., Wagaarachchi, P.T., Flett, G.M., Templeton, A. Mifepristone as a late post-coital contraceptive. Hum Reprod 2001, 16(1): 72-5.
100. van der Stege, J.G, Pahl-van Beest, E.H., Beerthuizen, R.J. et al. Effects of a preovulatory single low dose of mifepristone on ovarian function. Eur J Contracept Reprod Health Care 2006, 11(2): 104-8.
101. Marions, L., Hultenby, K., Lindell, I. et al. Emergency contraception with mifepristone and levonorgestrel: Mechanism of action. Obstet Gynecol 2002, 100(1): 65-71.
102. Ortiz, M.E., Ortiz, R.E., Fuentes, M.A., Parraguez, V.H., Croxatto, H.B. Post-coital administration of levonorgestrel does not interfere with post-fertilization events in the new-world monkey Cebus apella. Hum Reprod 2004, 19(6): 1352-6.
103. Chengalvala, M.V., Meade, E.H. Jr., Cottom, J.E. et al. Regulation of female fertility and identification of future contraceptive targets. Curr Pharm Des 2006, 12(30): 3915-28.